Summary & Overview
HCPCS Q5136: Denosumab-bbdz (Jubbonti/Wyost) Injection, 1 mg
HCPCS Level II code Q5136 denotes the injection of denosumab-bbdz (Jubbonti/Wyost), a biosimilar formulation of denosumab, at a 1 mg unit. This code matters nationally as biosimilar biologics expand therapeutic options and impact drug pricing, utilization patterns, and payer coverage policies across outpatient and infusion settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for denosumab biosimilars, the typical service settings in which Q5136 is billed, and the payer landscape relevant to coverage and reimbursement. The publication outlines national benchmarks where available, summarizes recent policy updates affecting biosimilar injectable coverage decisions, and explains implications for billing and claims workflows.
This summary equips clinicians, billing professionals, and policy analysts with a clear understanding of what Q5136 represents, which payers commonly encounter the code, and the topics covered in the full publication: utilization benchmarks, coverage policy trends for biosimilars, and clinical context for denosumab use. Data not available in the input will be explicitly noted in the detailed sections.
Billing Code Overview
HCPCS Level II code Q5136 represents an injection of denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg. This billing entry denotes the administration of a biosimilar version of denosumab, an antiresorptive monoclonal antibody used in conditions requiring inhibition of bone resorption.
Service Type: Drug administration / injectable biologic
Typical Site of Service: Outpatient infusion clinic, physician office, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or adult patient with osteoporosis or bone loss who requires subcutaneous monoclonal antibody therapy to reduce fracture risk. The patient presents to an outpatient infusion clinic, specialty injectable clinic, or physician office for administration of denosumab-bbdz (Q5136) dosed per product labeling. Clinical workflow includes verification of indication and recent bone mineral density or fracture history, medication reconciliation, screening for hypocalcemia and recent dental procedures, obtaining informed consent, documentation of lot number and dose, subcutaneous injection by an authorized clinician (e.g., nurse, advanced practice provider, or physician), observation for immediate adverse reaction (typically 15–30 minutes), and scheduling of follow-up dosing and monitoring (calcium, vitamin D adherence, and dental evaluation as indicated). Typical sites of service are outpatient infusion/injectable clinics, physician offices, and ambulatory care centers; administration may also occur in long-term care facilities for eligible residents.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use for routine, single-product administration when no special circumstances apply |